Management of Giant Hepatic Hemangiomas

Introduction to Hepatic Hemangiomas

• Hepatic hemangiomas are the most common benign mesenchymal hepatic tumors, with a strong female predominance and a female:male ratio of up to 5:1, as recognized by the American College of Radiology and the European Association for the Study of the Liver 1, 2, 3, 4
• Typical hemangioma features on MRI include high signal intensity on T2-weighted images and early peripheral nodular enhancement with progressive centripetal filling on dynamic contrast sequences, as reported by the European Association for the Study of the Liver and the American College of Radiology 1, 5

Diagnosis of Hepatic Hemangiomas

• The American College of Radiology recommends MRI with gadolinium contrast as the gold standard for diagnosis of hepatic hemangiomas, with 95-99% accuracy 1
• Initial screening modality of choice is ultrasound due to low cost and no radiation exposure 6
• Contrast-enhanced ultrasound (CEUS) reduces indeterminate diagnoses from 57% to 6% and correctly characterizes 80-90% of hemangiomas 1
• CT scan is less accurate than MRI but still useful, with early peripheral enhancement with progressive centripetal filling on dynamic contrast-enhanced CT, and becomes isoattenuating to liver in portal venous phase 2
• Key MRI sequences include:

Management of Asymptomatic Hemangiomas

• Asymptomatic hemangiomas should be managed conservatively, with observation without specific intervention recommended as the standard management approach for benign liver hemangiomas, regardless of size, as recommended by the American College of Gastroenterology and the American Association for the Study of Liver Diseases 4, 8, 1
• Ultrasound assessment should be performed regularly to track hemangioma size and characteristics, allowing for close monitoring of the hemangioma's growth and development, with the following frequency:

Management of Symptomatic Hemangiomas

• Intervention should be considered for symptomatic lesions, progressive enlargement, high-risk features, or size >10 cm with symptoms, with treatment options including surgical resection and transarterial embolization, and radiofrequency ablation having a limited role for smaller symptomatic lesions, as recommended by the American College of Radiology and other studies 3, 8, 4
• Liver biopsy should be avoided if imaging strongly suggests hemangiomas due to the risk of bleeding and low diagnostic yield for small lesions, but may be considered if imaging features are atypical or concerning for malignancy, as suggested by the American College of Radiology and other studies 1

Contraindications for Transarterial Embolization (TAE)

• The National Comprehensive Cancer Network recommends that TAE is contraindicated in patients with portal vein thrombosis, hepatic failure (bilirubin >3 mg/dL unless segmental treatment can be performed), Child-Pugh class C liver disease (unless bridging to transplant), elevated creatinine clearance (due to nephrotoxic contrast), and when the arterial supply to the tumor cannot be isolated 9
• Significant portal hypertension (hepatic vein pressure gradient >10 mmHg) is a contraindication for TAE, as recommended by the American Association for the Study of Liver Diseases 10
• Elevated bilirubin levels are also a contraindication for TAE, as stated by the European Association for the Study of the Liver 10
• Insufficient future liver remnant volume is a contraindication for TAE, as recommended by the European Association for the Study of the Liver 11
• Poor performance status or significant comorbidities are contraindications for TAE, as stated by the European Association for the Study of the Liver 11

Complications of TAE

• The National Comprehensive Cancer Network reports that TAE complications include post-embolization syndrome (pain, fever), non-target embolization, hepatic abscess formation, and biliary complications 9

Follow-up Imaging

• The National Comprehensive Cancer Network recommends follow-up imaging at 1, 3, and 6 months after TAE to assess response 9
• Post-surgical follow-up imaging at 3 months is necessary to confirm complete resection, with no long-term follow-up needed after complete resection, as recommended by the American College of Surgeons and other studies 4, 3
• Regular clinical follow-up with repeat liver function tests in 4-6 weeks is reasonable for patients with improving liver function tests and an incidental hemangioma, and imaging follow-up frequency should be based on hemangioma size, as recommended by the American College of Gastroenterology and other studies 8

Management of Hemangiomas in Pregnancy

• Vaginal delivery is the preferred method of delivery for pregnant patients with a known hepatic hemangioma, with cesarean section reserved only for specific high-risk cases or obstetric indications, as recommended by the European Association for the Study of the Liver (EASL) guidelines 4
• For most hemangiomas, especially those less than 5 cm, vaginal delivery is recommended, with consideration of assisted vaginal delivery to shorten the second stage if the hemangioma is greater than 5 cm, as suggested by the EASL guidelines 4
• Excessive Valsalva maneuvers during the pushing phase should be avoided to minimize the risk of complications, such as rupture or hemorrhage, in pregnant patients with hepatic hemangiomas 4
• Elective cesarean section should be considered for high-risk hemangiomas, including those with size >10 cm, peripheral/exophytic location >4 cm, or previous hemorrhagic complications, as recommended by the EASL guidelines 4
• The risk of spontaneous rupture during labor is rare but potentially catastrophic, emphasizing the importance of careful assessment and monitoring of hemangioma characteristics throughout pregnancy, as recommended by the EASL guidelines 4
• Peripheral location, exophytic growth pattern, size >10 cm, rapid growth, and pregnancy are associated with an increased risk of rupture, with the risk of rupture for liver hemangiomas being extremely low (<1%) for small lesions (<5 cm), but increasing to approximately 3.2% for giant hemangiomas (5-10 cm) and 5% for lesions greater than 10 cm, as reported by the Society of Interventional Radiology and other studies 3, 4, 1